DECIPARTICLES
Live / Allowed — Published for opposition (as of 31 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 07 Apr 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98487663
- Mark type
- Stylized text
- Filed
- 07 Apr 2024
- Published for opposition
- 31 Mar 2026
- Attorney of record
- Craig W. Mueller
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, drug preparations comprising small particles for enhanced absorption and therapeutic effect for the treatment of cancer, including pancreatic cancer, melanoma, skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, kidney cancer, stomach cancer, ovarian cancer, cervical cancer, liver cancer, multiple myeloma, lymphoma, glioma, glioblastoma, diffuse midline glioma, brain or spinal cancer, CNS tumors, HIV-AIDS, myelodysplastic disease, leukemia, hypertension, epilepsy, seizures, schizophrenia, bipolar disorder, psychosis, depressive disorder, dementia, obsessive-compulsive disorder, Huntington's disease, Parkinson's disease, fungal infection, hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, hyperglycemia, diabetes, inflammatory disease, obesity, fever, pain, asthma, bronchospasm, bacterial infection, pneumonia, pulmonary hypertension, and malaria; Drug delivery agents in the form of pharmaceutical preparations comprising small particles that facilitate the delivery of pharmaceutical preparations for the treatment of cancer, including pancreatic cancer, melanoma, skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, kidney cancer, stomach cancer, ovarian cancer, cervical cancer, liver cancer, multiple myeloma, lymphoma, glioma, glioblastoma, diffuse midline glioma, brain or spinal cancer, CNS tumors, HIV-AIDS, myelodysplastic disease, leukemia, hypertension, epilepsy, seizures, schizophrenia, bipolar disorder, psychosis, depressive disorder, dementia, obsessive-compulsive disorder, Huntington's disease, Parkinson's disease, fungal infection, hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, hyperglycemia, diabetes, inflammatory disease, obesity, fever, pain, asthma, bronchospasm, bacterial infection, pneumonia, pulmonary hypertension, and malaria
Owner
- Sapu Bioscience, LLC, Wanchai, DE, US
- Sapu Bioscience, LLC, Wanchai, DE, US
Prosecution history
- 31 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 31 Mar 2026 — PUBLISHED FOR OPPOSITION
- 25 Mar 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Mar 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 10 Mar 2026 — EXAMINER'S AMENDMENT ENTERED
- 10 Mar 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 10 Mar 2026 — EXAMINERS AMENDMENT E-MAILED
- 10 Mar 2026 — EXAMINERS AMENDMENT -WRITTEN
- 10 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 10 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 10 Feb 2026 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 16 Nov 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 16 Nov 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 20 Aug 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 20 Aug 2025 — FINAL REFUSAL E-MAILED